Search
Now showing items 1-6 of 6
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors
(Elsevier Masson SAS, 2017)
There are around 20 Cyclin-dependent kinases (CDKs) known till date, and various research groups have reported their role in different types of cancer. The X-ray structures of some CDKs especially CDK2 was exploited in the ...
Role of genomic alterations in HER2 positive breast carcinoma: Focus on susceptibility and trastuzumab-therapy
(Bentham Science Publishers B.V., 2017)
Background: Breast cancer is the most frequently diagnosed life-threatening malignancy among women, across the globe. HER2 positive is a distinct breast cancer subtype, on account of its unique biology and physiological ...
Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array
(Springer Verlag, 2018)
Purpose: Cyclophosphamide and doxorubicin (adjuvant chemotherapy) are commonly used to treat breast cancer patients. Variation in the genes involved in pharmacodynamics and pharmacokinetics of these drugs plays an important ...
Synthetic versus enzymatic pictet-spengler reaction: An overview
(Bentham Science Publishers B.V., 2018)
Background: Pictet-Spengler reactions is an irreplaceable part of cyclization reaction leading to the formation of indispensable heterocyclic moieties including imidazole, benzoxazole, pyrrole, indole and others having ...
Pharmacogenetics of Cyclophosphamide and Doxorubicin in Breast Cancer & Synthesis and Biological Evaluation of New Imidazole Based Putative Anticancer Agents
(Central University of Punjab, 2019)
Breast cancer is the second most prevalent cancer in women worldwide. It is treated by various strategies, including surgery, radiation therapy, hormonal therapy, targeted therapy and chemotherapy. Chemotherapeutic drugs ...
Computational investigation of binding mechanism of substituted pyrazinones targeting corticotropin releasing factor-1 receptor deliberated for anti-depressant drug design
(Taylor and Francis, 2019)
In spite of various research investigations towards anti-depressant drug discovery program, no one drug has not yet launched last 20 years. Corticotropin-releasing factor-1 (CRF-1) is one of the most validated targets for ...